Our
Speakers (A-Z)
Alexander Bastian
Vice President of Market Access at Galapagos NV
Alexander Bastian is Vice President of Market Access at Galapagos NV, a Belgo-Dutch company that develops therapies with proprietary, novel modes-of-action. Here Alex is leading the build-out of the global value and access function, helping to shape the pipeline of future products, and working with health care stakeholders to ensure that value is captured for patients and society from the medications Galapagos brings to regulatory approval.
Alexandre Passioukov
Vice President Translational Medicine at Pierre Fabre
Alexandre Passioukov leads translational medicine efforts across oncology, CNS and dermatology therapeutic areas at Pierre-Fabre R&D. Previously, Dr. Passioukov was leading translational medicine programs at Roche (Switzerland) with a special focus on immune-oncology drugs. Prior to joining Roche, Alexandre served as Head of Translational Research at EORTC in Brussels, conducting structural translational medicine activities of European clinical research networks.
Carla Leibowitz
Global head of healthcare partnerships at NVIDIA
Carla Leibowitz is a growth and innovation executive currently leading Corporate Development Arterys, the first company to achieve FDA clearances for several products and a platform that combine cloud computing and artificial intelligence in the medical imaging space. In her role, Carla oversees corporate strategy and planning, business development, geographic expansion and investor relations.
Christa Noehammer
Senior Scientist at the Austrian Institute of Technology
Christa Noehammer currently works as Senior Scientist at the Austrian Institute of Technology where she has been heading the Molecular Medicine research unit for several years. Holding a master degree in Microbiology and a PhD in Biochemistry she has been working in the microarray field since 1999 being involved in the design, production and data analysis of various microarray types thereby mainly focusing on minimally invasive biomarker discovery for cancer diagnostics.
Christophe Le Tourneau
Senior Medical Oncologist & Professor of Medicine at Institut Curie & Versailles-Saint-Quentin-en-Yvelines University
Christophe Le Tourneau is senior Medical Oncologist at the Institut Curie and Professor of Medicine at the Versailles-Saint-Quentin-en-Yvelines University. He is heading the Department of Drug Development and Innovation as well as the Head and Neck Clinic. Christophe Le Tourneau was certified in Medical Oncology in 2005 and got his PhD in Clinical Epidemiology in 2007.
David Henderson
Senior Biologist at Mironid
David Henderson is responsible for the efficient and effective delivery of lab based and collaborative research programs covering novel compound development, biomarker discovery and target validation. Prior to taking up this position with Mironid, David won a prestigious Innovation Fellowship at the Salk Institute for biological studies, San Diego, for his work in epigenetic dysregulation in precancerous disease.
Dolores J. Cahill
Professor of Translational Science at UCD School of Medicine, University College Dublin
Prof. Dr Dolores Cahill has over 25 years expertise in high-throughput protein array, antibody array, proteomics technology development, automation and their biomedical applications, including in biomarker discovery, diagnostics and personalised medicine. She is Professor of Translational Science, School of Medicine and at the Conway Institute at the University College Dublin (UCD) (2005-present).
Gary Pestano
Vice President, Development and Operations at Biodesix, Inc.
Dr. Gary Pestano leads the Development and Operations departments at Biodesix, a molecular diagnostics company. He is the New York State Clinical Laboratory Evaluation Program (CLEP) Laboratory Director in Boulder, CO of the company’s CLIA, CAP, CLEP, and ISO 13485 -certified laboratory.
James Godsey
Vice President, R&D, Clinical Sequencing Division at Thermo Fisher Scientific
Dr. James Godsey has an extensive background (30+ years) in Technology Discovery, Product Development and general management in the infectious disease and cancer diagnostic industry. He joined Thermo Fisher Scientific in 2015 as the Clinical Sequencing Division was established.
Jane Wilkinson
Senior Director, Genomics Platform Project & Alliance Management at Broad Institute
Jane Wilkinson is a Senior Director at the Broad Institute where she leads the Broad Genomics Alliance Management team. In this role, Jane manages the platform’s external collaborations and alliances, overseeing the successful implementation and execution. She also works to ensure that the platform meets complex goals from a variety of scientific project types with specific deliverables and deadlines of partnerships, as well as serving as an advocate for those partnerships.
Joana Brilhante
Head of Clinical Development at AIPES
Joana has a background in Nuclear Medicine imaging and a Masters of Science in Clinical Research. She worked in the clinic environment and has directed her career towards industry, working in the management of imaging operation in multicenter clinical trials. She has also been involved in the development of diagnostic and therapy novel PET tracers in EU and US markets.
Joanne Hackett
Chief Commercial Officer at Genomics England
Professor Joanne Hackett is the Chief Commercial Officer at Genomics England and lead member of the Business and Investment Committee.
As CCO, Joanne is responsible for Genomics England’s industry engagement strategy by developing, managing and accelerating relationships with commercial organisations − creating opportunities for collaboration both nationally and globally.
John Quackenbush
Chair of the Department of Biostatistics at the Harvard School of Public Health
John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard TH Chan School of Public Health and Professor of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute.
Jörg Engelbergs
Scientific Regulatory Expert Biomedicines at Paul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines
Dr. Jörg Engelbergs is currently working for the Paul-Ehrlich-Institut in Langen, Germany, as regulatory-scientific expert and assessor (Quality / CMC and Non-Clinic) for biopharmaceuticals with focus on Biotechs (Monoclonal Antibodies) and further as expert for IVDs / biomarker based Companion Diagnostics (CDx) and stratified / personalized (Bio-) Medicines.
Lauren C. Leiman
Executive Director at BloodPAC
Lauren Leiman is currently the Executive Director of the Blood Profiling Atlas in Cancer (BloodPAC), a consortium focused on creating an open database for liquid biopsies to accelerate the development of safe and effective blood profiling diagnostic technologies for patient benefit. Prior to running BloodPAC, she was the Senior Director of External Partnerships at White House Cancer Moonshot Task Force during the Obama Administration.
Lisa Mansell
Business Development Manager at Abingdon Health
Dr Lisa Mansell has 18 years of experience in the diagnostic industry including rapid lateral flow diagnostics, ELISA assays, and mass spectrometry methods. Lisa has a degree in Biomedical Science and a PhD in Forensic Toxicology. As Business Development Manager for Abingdon Health’s contract services business she is responsible for managing new lateral flow diagnostic development and manufacturing opportunities.
Ron van Schaik
Professor Pharmacogenetics Erasmus MC; President European Society for Pharmacogenomics & Personalised Therapy (ESPT)
Prof. Dr. Ron van Schaik (PhD, FACB) is a registered European Specialist Laboratory Medicine and a Full Professor of Pharmacogenetics. He is working at the Dept. Clinical Chemistry at the Erasmus University Medical Center Rotterdam, and is Director of the International (IFCC) Expert-center for Pharmacogenetics. Main interest is the clinical implementation of pharmacogenetics and pharmacogenetics translational research.
Simon Patton
Director at European Molecular Genetics Quality Network (EMQN)
Simon Patton, PhD is currently Director of the European Molecular Genetics Quality Network (EMQN) – the global leader in the provision of External Quality Assessment (EQA) schemes to diagnostic laboratories in the fields of genetics and pathology. He trained at the University of Liverpool in marine biology, before doing his doctorate in Genetics at the University of Cambridge. He is currently at Manchester University NHS Foundation Trust.
Stefan Kostense
Director, Biomarkers, Janssen (Johnson & Johnson).
After obtaining his PhD on HIV specific immunity, he joined Crucell/Janssen as a scientist, evaluating vaccine immunogenicity in preclinical models. He has set up up the Clinical Immunology department of 35 FTE, and set up a GLP and GCLP compliant laboratory including LIMS, for the analysis of toxicity and clinical samples, supporting the development of antibody therapeutics and vaccines. As department head he was responsible for the scientific strategy, operational efficiency, and effective outsourcing to CRO’s or collaboration with external key opinion leaders.
Tuc Ahmad
Scientific Director at Covance
Tuc is Scientific Director in the Covance Diagnostic Development team and based in Europe. He has responsibility as the primary scientific contact for Biopharma clients for initial engagement on new biomarker programs focused on discovery to provide a better understanding of therapeutic targets, molecular signaling, drug biology and patient response.
Yong-Jie Lu
Professor in Molecular Oncology at Barts Cancer Institute, Queen Mary University of London
Professor Yong-Jie Lu is a professor in Molecular Oncology at Barts Cancer Institute, The Barts and London School of Medicine and Dentistry, Queen Mary University of London. He completed his medical training in 1989 at Medical College, Zhengzhou University, then MD in 1992 at Harbin Medical University and PhD in 1995 at Cancer Institute/Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC).
